LXRX

Lexicon Pharmaceuticals Inc

$1.89

0.00 (0.00%) Today

0.01 (0.53%) Pre-market

— up— down

Compare LXRX

Market Cap

$837M+35.3%

Revenue (TTM)

$42.11M-29.0%

Net Income (TTM)

$-67,962,600

EPS (TTM)

-0.15

Shares Out

444.20M

Open

$1.88

Previous Close

$1.88

Day Range

$1.80 – $1.94

52-Week Range

$1.10 – $2.68

Beta

1.05

Earnings Date

Nov 13, 2026

Volume

3.94M

Avg Volume

3.22M

Analyst Rating

Buy

Exchange

NASDAQ NMS - GLOBAL MARKET

About LXRX

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.